Cereno Scientific

Cereno Scientific has strengthened CS1’s commercial positioning with a third Canadian patent, extending protection in a strategically important pharmaceutical market. The patent, granted within CS1’s third patent family, covers delayed-release formulations...

Cereno Scientific has announced that its third asset, CS585 (a potent and selective agonist of the prostacyclin receptor), will be tested in preclinical disease model studies relating to antiphospholipid syndrome (APS), a rare autoimmune disease associated...